SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nasdaq, Inc. is a holding company, which engages in trading, clearing, exchange technology, regulatory, securities listing, information, and public and private company services. It operates through the following segments: Capital Access Platforms, Financial Technology, and Market Services. The Capital Access Platforms segment delivers liquidity, transparency, and integrity to the corporate issuer and investment community by empowering clients to effectively navigate the capital markets, achieve their sustainability goals, and drive governance excellence. The Financial Technology segment offers platforms that improve the liquidity, transparency, and integrity of the global economy by architecting and operating the markets. The Market Services segment includes equity derivative trading and clearing, cash equity trading, fixed income, currency, and commodities trading. The company was founded by Gordon S. Macklin in 1971 and is headquartered in New York, NY.

Nasdaq Inc - Ordinary Shares - 144A

Nasdaq Inc

Nasdaq Inc. is trending as investors monitor the exchange's push for 23-hour trading amid broader volatility and uncertainty regarding government data availability and geopolitical tensions. The community is actively debating the sustainability of current AI-driven market valuations and the impact of potential shifts in monetary policy as they analyze recent performance and historical cycle indicators.

Dow, Inc. is a holding company, which engages in the development of innovative solutions. It operates through the following segments: Packaging and Specialty Plastics, Industrial Intermediates and Infrastructure, and Performance Materials and Coatings. The Packaging and Specialty Plastics segment consists of hydrocarbons and energy and packaging and specialty plastics. The Industrial Intermediates and Infrastructure segment covers the industrial solutions and polyurethanes, and construction of chemicals. The Performance Materials and Coatings segment includes coatings and performance monomers, and consumer solutions. The company was founded in 1897 and is headquartered in Midland, MI.

Dow Inc

Dow Inc. is drawing significant community attention as it navigates a challenging petrochemical market landscape, with participants actively debating the impact of global supply chain disruptions and recent corporate restructuring efforts. Investors are closely monitoring the company's dividend sustainability and operational turnaround strategy as the stock trends near long-term lows, sparking intense discussion regarding its valuation versus potential cyclical recovery.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is trending as investors digest a recent $550 million convertible note offering, which some view as a strategic move to extend runway for clinical pipeline development despite immediate share price pressure. The community remains deeply divided between long-term bulls betting on a potential buyout or major trial catalysts later this year, and frustrated traders venting over persistent management-related sell-offs and the stock's struggle to sustain price momentum.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is experiencing intense market volatility and a sharp sell-off following a series of major corporate announcements, including the appointment of a new CEO and a significant capital raise through a follow-on offering. Investors are expressing deep frustration over ongoing share dilution, while the community remains sharply divided between those viewing the current valuation as a distressed 'generational buying opportunity' and those warning of imminent bankruptcy and further reverse splits.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is attracting intense community attention as part of a broader nuclear energy revival, fueled by growing demand for 24/7 power from AI data centers and new federal initiatives for space-based nuclear reactors. While some investors are accumulating shares on weakness and eyeing a long-term recovery, others are deeply concerned by the stock's significant decline, persistent short interest, and ongoing corporate divestment, leading to heated debates over whether this is a structural buying opportunity or a speculative value trap.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is seeing active community debate as investors weigh long-term utility goals against frustration over stagnant price action and the emergence of Janction. While some traders are focused on technical resistance levels and accumulation strategies, others are vocal about their skepticism regarding the project's roadmap and leadership communication.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is trending following a strong quarterly earnings report that topped revenue and profit expectations, signaling robust growth in same-store sales and aggressive store expansion. Investors are actively debating the company's premium valuation compared to industry peers like Chipotle, with community sentiment split between enthusiasm for its rapid unit growth and skepticism regarding its long-term margin sustainability.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph is trending as investors debate the potential for enterprise-grade adoption while monitoring ongoing volatility and supply distribution. Community members are actively split between those accumulating in anticipation of a breakthrough driven by institutional use cases and those frustrated by stagnant price action.

TSS, Inc. engages in the provision of comprehensive services for the planning, design, development and maintenance of mission-critical facilities and information infrastructure as well as integration services. It operates through the Facilities and Systems Integration Services business segments. The Facilities segment consists of the design, project management, and maintenance of data center and mission-critical business operations. The Systems Integration segment integrates information technology equipment for original equipment manufacturer vendors and customers to be used inside data center environments, including modular data centers. The company was founded by Gerard J. Gallagher on December 20, 2004 and is headquartered in Georgetown, TX.

TSS Inc

TSS Inc. is trending after reporting record quarterly results that significantly surpassed analyst expectations, fueled by a surge in high-margin AI systems integration and a two-year contract extension with its primary partner, Dell. Community sentiment is divided, with bullish investors highlighting the company's vital role in data center buildouts and potential for a squeeze against high short interest, while skeptics point to the stock's dependence on a single major customer and lack of specific revenue guidance.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing extreme volatility following a massive surge and subsequent sharp decline, with community members fiercely debating whether the token is a legitimate project or a textbook pump-and-dump scheme. The project has publicly denied involvement in the price manipulation, while on-chain data and analyst warnings regarding highly concentrated token ownership continue to fuel intense speculation and caution among investors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Short Interest Update

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) was the target of a significant growth in short interest in the month of March. As of March 31st, there was short interest totaling 10,843,213 shares, a growth of 31.7% from the March 15th total of 8,233,141 shares. Currently, 10.8% of...

Viridian Therapeutics (NASDAQ:VRDN) Trading Up 5.2% - What's Next?

Viridian Therapeutics (NASDAQ:VRDN) Trading 5.2% Higher - Here's What Happened...

Wedbush Lowers Viridian Therapeutics (NASDAQ:VRDN) Price Target to $31.00

Wedbush cut their price objective on shares of Viridian Therapeutics from $37.00 to $31.00 and set an "outperform" rating for the company in a report on Wednesday...

Top 3 Health Care Stocks Which Could Blast Off This Quarter

Undervalued companies in health care sector with low RSI values present buying opportunity: PepGen Inc (PEPG), KALA BIO Inc (KALA), Viridian Therapeutics Inc (VRDN)read more...

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Rating of "Moderate Buy" by Analysts

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the fifteen research firms that are presently covering the...

The Goldman Sachs Group Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $31.00

The Goldman Sachs Group cut their price target on Viridian Therapeutics from $36.00 to $31.00 and set a "buy" rating on the stock in a research note on Tuesday...

AMGN's Subcutaneous Tepezza Scores Phase III Win in Thyroid Eye Disease

Amgen's subcutaneous Tepezza hits phase III goals in thyroid eye disease, matches IV efficacy and offers faster dosing that could expand access.

Royal Bank Of Canada Has Lowered Expectations for Viridian Therapeutics (NASDAQ:VRDN) Stock Price

Royal Bank Of Canada lowered their price target on Viridian Therapeutics from $42.00 to $30.00 and set an "outperform" rating for the company in a report on Tuesday...

<ul class="summary-bullets"><li>Amgen’s Phase 3 trial met its primary goal, with 77% of patients showing a strong improvement in eye bulging.</li><li>Stifel analyst Alex Thompson noted the higher proptosis rate but said Viridian’s Elegrobar could better stand out in the market.</li><li>Elegrobart reduced eye bulging by about 54% with the four-week regimen and 63% with the eight-week regimen.</li></ul>Shares of Viridian Therapeutics (VRDN) plunged 23% on Monday to their lowest since June 3, 2025, extending a sharp selloff that began on March 30.Viridian shares&nbsp;had crashed last Monday after the firm <a href="https://stocktwits.com/news-articles/markets/equity/why-is-vrdn-stock-falling-today/cZERVHrRIZDk-in-thyroid-eye-disease-trials/cZ7xqdaRI83">reported</a> the Phase 3 results for Elegrobart in thyroid eye disease. While the study met its primary goal, showing strong reductions in eye bulging compared with placebo, improvements in inflammation were limited, and there were also reports of tinnitus.<h2 class="st-heading-2">Why Did The Stock Crash Today?</h2><a href="https://stocktwits.com/symbol/VRDN">VRDN shares</a> fell after Amgen reported positive results from a Phase 3 trial of Tepezza for thyroid eye disease. The study met its main goal, with 77% of patients showing a strong improvement in eye bulging over 24 weeks.Following the results, Stifel analyst Alex Thompson said Amgen’s Phase 3 results, with a 77% rate of proptosis response, were higher than Viridian’s Elegrobar, according to The Fly. However,&nbsp;Thomson noted that Viridian’s drug uses a simpler subcutaneous injection instead of an on-body infusion, which could help it stand out in the market. The analyst maintained a ‘Buy’ rating on Viridian shares.The Viridian REVEAL-1 trial met its main and key secondary goals at week 24. The study tested two dosing schedules, every four weeks and every eight weeks, against a placebo. Elegrobart reduced eye bulging by about 54% with the four-week regimen and 63% with the eight-week regimen, compared to roughly 18% for placebo.Topline results from REVEAL-2, the second Phase 3 trial in chronic thyroid eye disease, are expected in the second quarter (Q2) of 2026. The company plans to submit a Biologics License Application (BLA) to the FDA in the first quarter (Q1) of 2027.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits changed to ‘bullish’ from ‘extremely bullish’ a day earlier, amid ‘extremely high’ message volumes.Chatter was largely positive despite the intraday slump, with one user calling the selloff “overdone.”<stembedurl>https://stocktwits.com/TKkamen/message/649478692</stembedurl>Another user expects the stock to climb to $25 by the end of the week. It is currently trading below $15.<stembedurl>https://stocktwits.com/Cracker36/message/649473609</stembedurl>Year-to-date, the stock has slumped more than 50%.Read also: <a href="http://stocktwits.com/news-articles/markets/equity/smx-stock-priming-for-multi-day-run-new-tracking-platform-pushes-shares-higher/cZJ4qGJRIYL">Is SMX Stock Priming For Another Multi-Day Run? New Tracking Platform Pushes Shares Up By 75%</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

S&P 500 Index trades listlessly ahead of Nvidia earnings. 

VRDN Stock Falls To 9-Month Lows – What’s The Amgen Connection?

Viridian shares continued to tumble after Amgen’s thyroid eye disease treatment trial showed a higher proptosis response rate.

Equity

Why Is Viridian Therapeutics Stock Sinking Monday?

Viridian shares fall after Amgen TEPEZZA Phase 3 data shows stronger efficacy, raising concerns over elegrobart's position in the TED market.read more...

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$1.08	--	--	N/A
Q4 '25	-$0.98	-$1.08	-10.24%	MISSED
Q3 '25	-$1.02	-$0.34	66.62%	BEAT
Q2 '25	-$1.00	-$1.00	0.09%	BEAT
Q1 '25	-$0.97	-$0.87	10.01%	BEAT

VRDN
Viridian Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest VRDN News

VRDNViridian Therapeutics Inc